Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to six newly hired non-executive employees on June 1, 2026 under Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to six newly hired non-executive employees on June 1, 2026 under Nasdaq Listing Rule 5635(c)(4).
The grants are non-qualified stock options for an aggregate 372,000 shares at a $24.88 exercise price, with a 10-year term and four-year vesting schedule.
Details
News Market Reaction – DMRA
On Jun 1, the day this news came out, DMRA closed 0.12% below the previous close.
Data tracked by StockTitan Argus for the Jun 1 session.
Key Figures
- Option grant size
- 372,000 shares
- Aggregate non-qualified options in June 1, 2026 inducement grants
- Exercise price
- $24.88 per share
- Exercise price for inducement stock options
- Option term
- 10 years
- Term of non-qualified stock options in inducement grants
- Employees receiving grants
- 6 employees
- Newly hired non-executive employees granted options
- Cliff vesting portion
- 25%
- Portion of options vesting on first anniversary of start date
- Remaining vesting period
- 36 months
- Monthly vesting period after initial 1-year cliff
Historical Context
-
Cash runway to 2029 and multiple planned regulatory submissions and datasets.
-
Small option grants to new hires under 2022 Inducement Plan.
-
Equity awards to new CEO and hires under inducement framework.
-
Appointment of new CEO and additional industry veterans to board.
-
Large net loss driven by acquired in-process R&D charge and higher expenses.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
inducement grants financial
non-qualified stock options financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common stock with a 10-year term and an exercise price of
About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.
Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.